Search Results - Baba, Emna

  • Showing 1 - 2 results of 2
Refine Results
  1. 1
    Safety and immunogenicity of a modified mRNA-lipid nanoparticle vaccine candidate against COVID-19: Results from a phase 1, dose-escalation study

    Safety and immunogenicity of a modified mRNA-lipid nanoparticle vaccine candidate against COVID-19: Results from a phase 1, dose-escalation study by Essink, Brandon J, Shapiro, Craig, Isidro, Marie Grace Dawn, Bradley, Paul, Pragalos, Antoinette, Bloch, Mark, Santiaguel, Joel, Frias, Melchor Victor, Miyakis, Spiros, Alves de Mesquita, Margarida, Berrè, Stefano, Servais, Charlotte, Waugh, Natasha, Hoffmann, Claudia, Baba, Emna, Schönborn-Kellenberger, Oliver, Wolz, Olaf-Oliver, Koch, Sven D, Ganyani, Tapiwa, Boutet, Philippe, Mann, Philipp, Mueller, Stefan O, Ramanathan, Roshan, Gaudinski, Martin Robert, Vanhoutte, Nicolas

    Get full text
    Items that this one cites
    Article
    Save to List
    Saved in:
  2. 2
    Introduction or Discontinuation of Additional Risk Minimisation Measures During the Life Cycle of Medicines in Europe

    Introduction or Discontinuation of Additional Risk Minimisation Measures During the Life Cycle of Medicines in Europe by Francisca, Reynold D. C., Baba, Emna, Hoeve, Christina E., Zomerdijk, Inge M., Sturkenboom, Miriam C. J. M., Straus, Sabine M. J. M.

    Published in Drug safety
    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:

Search Tools: